Randomised phase 3 trial of radiation plus androgen deprivation therapy with or without enzalutamide for high risk, clinically localised, prostate cancer
Primary Sponsor
ANZUP
Collaborating Groups
Trans Tasman Radiation Oncology Group (TROG), NHMRC Clinical Trials Centre
Accrual Target
800
Final Accrual
802
Closing Date of Accrual
30 June 2018
Trial Contact
enzarad.study@sydney.edu.au
Related Post
21 October, 2025
Grandad’s mission to walk 10,000 steps a day to support cancer research
LATEST NEWS: 21 October 2025 Walking at least 10,000
24 September, 2025
Prostate Cancer Month: Focus on the TROG Genitourinary Working Party
To mark Prostate Cancer Month in September, we asked